TargED Biopharmaceutical
TargED Biopharmaceuticals develops biological drugs that utilize small antibodies to deliver enzymes directly to blood clots for targeted thrombolysis. Its lead compound, TGD001, is designed to treat various thrombotic disorders, including Acute Ischemic Stroke and Immune Thrombotic Thrombocytopenic Purpura. The technology aims to accelerate the breakdown of blood clots regardless of their specific composition.
Visit websiteUtrecht, Netherlands
Biotechnology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €39.0M
- Funding rounds
- 1
Investors in TargED Biopharmaceutical
Investors on record for TargED Biopharmaceutical. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like TargED Biopharmaceutical?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors